SEC Form 4 · accession 0001104659-16-131386

Syros Pharmaceuticals, Inc. · SYRS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Jul 6, 2016

Accepted (ET)

Jul 6, 2016 · 9:23 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001556263

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jul 6, 2016	C	146,666	—	A	146,666	D
Common Stock^F1,F2	Jul 6, 2016	C	40,000	—	A	40,000	I	See Footnote
Common Stock^F1,F3	Jul 6, 2016	C	40,000	—	A	40,000	I	See Footnote
Common Stock^F1,F4	Jul 6, 2016	C	40,000	—	A	40,000	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A-2 Preferred Stock^F1	—	Jul 6, 2016	C	550,000	D	—	—	Common Stock	146,666	D
Series A-2 Preferred Stock^F2,F1	—	Jul 6, 2016	C	150,000	D	—	—	Common Stock	40,000	I
Series A-2 Preferred Stock^F3,F1	—	Jul 6, 2016	C	150,000	D	—	—	Common Stock	40,000	I
Series A-2 Preferred Stock^F4,F1	—	Jul 6, 2016	C	150,000	D	—	—	Common Stock	40,000	I

F1The Series A-2 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F2By Ann H. Sharp and Christine S. Carey, as Trustees of the Phillip A. Sharp 2008 Irrevocable Trust f/b/o Christine S. Carey.
F3By Ann H. Sharp and Helena S. Gordon, as Trustees of the Phillip A. Sharp 2008 Irrevocable Trust f/b/o Helena H. Sharp.
F4By Ann H. Sharp and Sarah S. Brokaw, as Trustees of the Phillip A. Sharp 2008 Irrevocable Trust f/b/o Sarah S. Brokaw.